ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 221

Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study

Sirisha Mitnala1, Amanda Phipps-Green2, Christopher Franklin1, Anne Horne3, Lisa K. Stamp4, Tony R. Merriman5 and Nicola Dalbeth1,3, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand, 4Medicine, University of Otago, Christchurch, Christchurch, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: gout

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Hyperuricaemia and secondary
gout are well-recognised complications of diuretic use.  Variants in ABCG2 and SLC2A9 have
been identified as the two major genetic risk factors for gout in genome wide
association studies. The aim of this study was to examine the clinical and
genetic characteristics of diuretic-associated gout. 

Methods:  Participants (n=1,365), all fulfilling
the 1977 ARA gout classification criteria, were recruited from primary and
secondary care.  All participants
attended a study visit, which included a detailed clinical assessment.  Use of diuretic therapy at the time of
recruitment was recorded, and was confirmed by electronic dispensing data.  The gout-associated ABCG2 rs2231142 and SLC2A9
rs11942223
SNPs were genotyped.  Clinical
and genetic features of diuretic-associated gout were analysed using a
case-control study design (diuretics vs. no diuretics).  Loop and thiazide diuretics were also
analysed separately (participants taking both loop and thiazide diuretics were
included in loop diuretic group).

Results:
 There were
939 participants on no diuretics and 426 participants on at least one diuretic
(281 in the loop diuretic group and 145 in the thiazide diuretic group).  In the diuretic group, there were more women,
later onset of disease, higher rates of cardiac disease, hypertension and type 2 diabetes, higher body mass index, higher serum urate and
lower eGFR, compared to those not on diuretics (Table).  Gout disease duration, frequency of gout
flares and presence of tophi were similar in the two groups (Table).  The ABCG2
rs2231142 minor (risk) allele was present
less frequently in the diuretic group (36.1%) than in those not on diuretics
(47.6%, p=
2.9E-04).  ABCG2 rs2231142 minor
(risk) allele positivity was lower in those taking loop diuretics (37.1%) and
thiazide diuretics (34.3%).  In contrast,
there was no significant difference in positivity for the minor (protective)
allele for SLC2A9 rs11942223 between
the two groups (p=
0.074).

Conclusion: Diuretic-associated gout represents a medically complex condition
with frequent comorbid conditions.  The observed
differences in the ABCG2 risk allele frequency
suggest that some genetic factors play a less dominant role in the etiology of
diuretic-associated gout, compared to primary gout. 

Table:
Clinical and genetic features separated by use of diuretics.
Unless specified, data are presented as mean (SD). For genotype
analysis,
p values were generated by logistic
regression adjusting for ancestral group.

No diuretic

(n=939)

Diuretic

(n=426)

p

Male sex, n (%)

829 (88.3%)

299 (70.2%)

2.9E-16

Age, years

53.9 (14.2)

65.3 (11.9)

8.3E-48

Age of onset, years

39.8 (14.8)

51.1 (17.4)

3.5E-28

Duration of gout, years

14.1 (11.8)

14.3 (13.6)

0.82

Māori or Pacific ancestry

553 (58.9%)

220 (51.6%)

0.013

Cardiac disease, n (%)

174 (18.6%)

262 (61.9%)

1.1E-56

Hypertension, n (%)

407 (44.2%)

353 (83.3%)

5.3E-41

Type 2 diabetes, n (%)

120 (13.0%)

146 (34.5%)

2.9E-20

Number of gout flares in previous year

6.6 (10.6)

6.0 (10.7)

0.37

Presence of tophi, n (%)

210 (23.0%)

107 (25.9%)

0.25

Body mass index, kg/m2

33.1 (6.9)

34.8 (8.7)

7.2E-04

Highest recorded serum urate, mg/dL

8.5 (2.0)

9.0 (2.2)

1.4E-05

eGFR, mL/min/1.73m2

68.5 (18.8)

50.2 (19.5)

1.4E-46

SLC2A9 rs11942223 protective allele (C) present, n (%)

139 (15.5%)

54 (13.3%)

0.074

ABCG2 rs2231142 risk allele (T) present, n (%)

426 (47.6%)

146 (36.1%)

2.9E-04


Disclosure: S. Mitnala, None; A. Phipps-Green, None; C. Franklin, None; A. Horne, None; L. K. Stamp, None; T. R. Merriman, None; N. Dalbeth, None.

To cite this abstract in AMA style:

Mitnala S, Phipps-Green A, Franklin C, Horne A, Stamp LK, Merriman TR, Dalbeth N. Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-and-genetic-characteristics-of-diuretic-associated-gout-a-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-genetic-characteristics-of-diuretic-associated-gout-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology